🌐 Entity
Duchenne muscular dystrophy
Type of muscular dystrophy
📊 Rating
3 news mentions · 👍 0 likes · 👎 0 dislikes
📌 Topics
- Biotech Analysis (1)
- Stock Ratings (1)
- Medical Research (1)
- Conference Presentation (1)
- Stock Market Analysis (1)
- Biotechnology Clinical Trials (1)
- Investment Outlook (1)
🏷️ Keywords
DMD (2) · Dyne Therapeutics (1) · Stifel (1) · stock rating (1) · Duchenne Muscular Dystrophy (1) · biotech (1) · clinical data (1) · Catalyst (1) · Duchenne muscular dystrophy (1) · MDA conference (1) · research presentation (1) · muscular dystrophy (1) · medical conference (1) · Guggenheim (1) · PepGen (1) · Stock Price Target (1) · Clinical Trials (1) · Biotechnology (1) · Pharmaceutical Investments (1) · PepFect Technology (1)
📖 Key Information
Duchenne muscular dystrophy (DMD) is a severe type of muscular dystrophy predominantly affecting boys. The onset of muscle weakness typically begins around age four, with rapid progression. Initially, muscle loss occurs in the thighs and pelvis, extending to the arms, which can lead to difficulties in standing up.
📰 Related News (3)
🔗 Entity Intersection Graph
People and organizations frequently mentioned alongside Duchenne muscular dystrophy:
-
🌐
DMD · 2 shared articles
-
Catalysis · 1 shared articles -
Stifel · 1 shared articles -
Clinical trial · 1 shared articles -
Biotechnology · 1 shared articles -
🌐
Guggenheim · 1 shared articles